PASG
−$51K
75,007 sh @ $1
ORBIMED ADVISORS LLC
Director, 10% Owner · SEC CIK 1055951
Insider at
STTK Shattuck Labs, Inc.
QTTB Q32 Bio Inc.
SION Sionna Therapeutics, Inc.
TRAW Traws Pharma, Inc.
PRLD Prelude Therapeutics Inc
IMA ImageneBio, Inc.
ACET Adicet Bio, Inc.
KROS Keros Therapeutics, Inc.
PMVP PMV Pharmaceuticals, Inc.
TSBX Turnstone Biologics Corp.
IKNA ImageneBio, Inc.
CRVS Corvus Pharmaceuticals, Inc.
PASG Passage BIO, Inc.
NPCE NeuroPace Inc
XTNT Xtant Medical Holdings, Inc.
CMPX Compass Therapeutics, Inc.
EWTX Edgewise Therapeutics, Inc.
IRON Disc Medicine, Inc.
MBX MBX Biosciences, Inc.
Advertisement
Buy track record
How this insider's open-market purchases have performed52%
of buys now in profit
12 up · 11 down
Avg return since buy+65.7%
Median return+5.8%
Best trade+397.0%
Worst trade−79.6%
Buys scored23
Average return by holding period — separates good entry timing from riding one long winner
After 1 month
+11.0%
43% won · 21 trades
After 3 months
−7.1%
22% won · 18 trades
After 6 months
+25.5%
44% won · 18 trades
After 12 months
+79.5%
50% won · 14 trades
| Date | Company | 90d trend | Buy price | Value | ΔOwn | 1M | 3M | 6M | 12M | To date |
|---|---|---|---|---|---|---|---|---|---|---|
| May 28, 2026 | QTTB | $8 | $10M | +55% | — | — | — | — | +22.6% | |
| May 28, 2026 | QTTB | $8 | $5M | NEW | — | — | — | — | +22.6% | |
| Apr 21, 2026 | PRLD | $4 | $7.5M | +17% | −6.3% | — | — | — | −2.8% | |
| Apr 21, 2026 | PRLD | $4 | $5M | NEW | −6.3% | — | — | — | −2.8% | |
| Apr 16, 2026 | TRAW | $2 | $998.2K | +99% | +45.5% | — | — | — | +5.8% | |
| Oct 8, 2025 | ACET | $1 | $1.5M | +20% | −29.3% | −45.6% | −55.9% | — | −45.8% | |
| Oct 8, 2025 | ACET | $1 | $3.5M | +353% | −29.3% | −45.6% | −55.9% | — | −45.8% | |
| Aug 25, 2025 | STTK | $1 | $4.56M | NEW | +130.4% | +102.2% | +307.4% | — | +397.0% | |
| Aug 25, 2025 | STTK | $1 | $912K | NEW | +130.4% | +102.2% | +307.4% | — | +397.0% | |
| Apr 3, 2025 | EWTX | $20 | $7.5M | +2.6% | +21.8% | −4.1% | +15.2% | +141.8% | +156.5% | |
| Apr 3, 2025 | EWTX | $20 | $2.5M | +39% | +21.8% | −4.1% | +15.2% | +141.8% | +156.5% | |
| Feb 18, 2025 | MBX | $11 | $531.9K | +1.5% | −22.8% | +11.5% | +33.7% | +269.8% | +225.8% | |
| Feb 18, 2025 | MBX | $11 | $1.02M | +14% | −22.8% | +11.5% | +33.7% | +269.8% | +225.8% | |
| Feb 14, 2025 | MBX | $10 | $177.8K | +0.6% | −16.4% | −2.3% | +26.9% | +278.3% | +241.1% | |
| Feb 14, 2025 | MBX | $10 | $291K | +0.9% | −16.4% | −2.3% | +26.9% | +278.3% | +241.1% | |
| Feb 10, 2025 | SION | $18 | $9.9M | +17% | −33.0% | −42.0% | −9.9% | +70.9% | +61.5% | |
| Jan 25, 2024 | ACET | $2 | $4.42M | +32% | −2.0% | −26.7% | −38.9% | −63.2% | −79.6% | |
| Jan 25, 2024 | ACET | $2 | $581.3K | +32% | −2.0% | −26.7% | −38.9% | −63.2% | −79.6% | |
| Jan 25, 2024 | ACET | $2 | $2.5M | +486% | −2.0% | −26.7% | −38.9% | −63.2% | −79.6% | |
| Jun 27, 2023 | ACET | $2 | $261.3K | +14% | +17.4% | −32.4% | −17.4% | −37.1% | −76.4% | |
| Jun 27, 2023 | ACET | $2 | $522.5K | +63% | +17.4% | −32.4% | −17.4% | −37.1% | −76.4% | |
| Jun 27, 2023 | ACET | $2 | $923.8K | +8.4% | +17.4% | −32.4% | −17.4% | −37.1% | −76.4% | |
| Jun 27, 2023 | ACET | $2 | $121.2K | +8.4% | +17.4% | −32.4% | −17.4% | −37.1% | −76.4% |
How this is calculated. We score only open-market purchases (SEC code
P) — the buys that carry real signal. Each trade's return is measured from the adjusted closing price on the purchase date to the latest close, accounting for stock splits and dividends. The 1M/3M/6M/12M columns show the same trade's return after each fixed holding period; a dash means that horizon hasn't elapsed yet or isn't priceable. Sales are excluded because insiders sell for many routine reasons. With only 23 scored trades, treat this as a small sample, not a verdict.
Advertisement
Open-market buys
$70.22M
23 trades
Open-market sells
$114.54M
78 trades
Net flow
−$44.32M
Net selling
Total filings
106
transactions shown
Full transaction history
All Form 4 activity across every company, newest firstPASG
−$37.3K
52,536 sh @ $1
PASG
−$15K
19,481 sh @ $1
PASG
−$138.2K
230,321 sh @ $1
PASG
−$64
80 sh @ $1
Advertisement
PASG
−$6.4K
8,015 sh @ $1
PASG
−$45.5K
54,181 sh @ $1
PASG
−$17.1K
20,903 sh @ $1
PASG
−$60.2K
76,200 sh @ $1
ACET
Orbimed Advisors Llc, ACET's 10% owner, spent $4.42M of their own money on 1.84M shares at $2, growing their stake 32%.
+$4.42M
1.84M sh @ $2
ACET
Orbimed Advisors Llc, ACET's 10% owner, spent $581.3K of their own money on 242,200 shares at $2, growing their stake 32%.
+$581.3K
242,200 sh @ $2
ACET
Orbimed Advisors Llc, ACET's 10% owner, spent $2.5M of their own money on 1.04M shares at $2, growing their stake 486%.
+$2.5M
1.04M sh @ $2
ACET
Orbimed Advisors Llc, ACET's 10% owner, spent $261.3K of their own money on 125,000 shares at $2, growing their stake 14%.
+$261.3K
125,000 sh @ $2
ACET
Orbimed Advisors Llc, ACET's 10% owner, spent $522.5K of their own money on 250,000 shares at $2, growing their stake 63%.
+$522.5K
250,000 sh @ $2
ACET
Orbimed Advisors Llc, ACET's 10% owner, spent $923.8K of their own money on 442,000 shares at $2, growing their stake 8%.
+$923.8K
442,000 sh @ $2
ACET
Orbimed Advisors Llc, ACET's 10% owner, spent $121.2K of their own money on 58,000 shares at $2, growing their stake 8%.
+$121.2K
58,000 sh @ $2
Frequently asked questions
How is ORBIMED ADVISORS LLC's win rate calculated?
We take every open-market purchase (SEC code P) we can match to a stock price, then compare the split- and dividend-adjusted price on the purchase date to the most recent close. The win rate is the share of those buys currently trading above the purchase price. Sales and share grants are not scored.
Why are some buys not included in the score?
A purchase is excluded if we can't price it — for example if the ticker is missing from the filing, the company has been delisted, or the security isn't a common stock we can match to market data. Excluded counts are shown next to the scored total.
What do the 1M / 3M / 6M / 12M columns mean?
They show each purchase's return after a fixed holding period — one, three, six, and twelve months from the buy date — using split- and dividend-adjusted prices. This separates good entry timing from simply holding a long-running winner. A dash means that horizon hasn't elapsed yet for that trade, or the stock couldn't be priced at that date.
Does a high win rate mean I should copy this insider?
No. Past performance does not predict future results, sample sizes are often small, and an insider's edge in their own company doesn't transfer to yours. This is context, not a recommendation. InsiderSource is not investment advice.
Where does this data come from?
Trades come from ORBIMED ADVISORS LLC's SEC Form 4 filings on EDGAR. Prices come from public market data and are split/dividend-adjusted. Always verify against the original filings before acting.